Title
Category
Credits
Event date
Cost
Recorded What is Long COVID?
  • Alabama Community Engagement Alliance against COVID-19 Disparities (Alabama CEAL)
  • 1.20 ABN
  • 1.00 ACPE Pharmacy
$0.00
ALAHOPE Recorded Course - Pharmacology of Opioids, Stimulants, and Benzodiazepines
  • ALAHOPE Substance Use
  • 0.60 ABN
  • 0.50 ABSWE
  • 0.50 ACPE Pharmacy
  • 0.50 ACPE Technician
  • 0.50 ABO
  • 0.50 ABP
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
  • 0.50 BDEA
$0.00
An interactive, online training session regarding the pharmacology of opioids, stimulants, and benzodiazepines.
ALAHOPE Recorded Course - Substance Use Disorder and Social Determinants of Health
  • ALAHOPE Substance Use
  • 0.30 ABN
  • 0.25 ABSWE
  • 0.25 ACPE Pharmacy
  • 0.25 ACPE Technician
  • 0.25 ABO
  • 0.25 ABP
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Attendance
  • 0.25 BDEA
$0.00
An interactive, online training session regarding substance use disorders (SUDs) and social determinants of health (SDOH).
ALAHOPE Recorded Course - Maternal Child Health and Substance Use Disorder
  • ALAHOPE Substance Use
  • 0.90 ABN
  • 0.75 ABSWE
  • 0.75 ACPE Pharmacy
  • 0.75 ACPE Technician
  • 0.75 ABO
  • 0.75 ABP
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
  • 0.75 BDEA
$0.00
An interactive, online training session regarding maternal child health and substance use disorder.
ALAHOPE Recorded Course - Substance Use Disorder Legal and Ethical Considerations
  • ALAHOPE Substance Use
  • 0.90 ABN
  • 0.75 ABSWE
  • 0.75 ACPE Pharmacy
  • 0.75 ACPE Technician
  • 0.75 ABO
  • 0.75 ABP
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
  • 0.75 BDEA
$0.00
An interactive, online training session regarding the legal and ethical considerations of substance use disorder.
ALAHOPE Recorded Course - Substance Use Disorder in the Emergency Department
  • ALAHOPE Substance Use
  • 0.90 ABN
  • 0.75 ABSWE
  • 0.75 ACPE Pharmacy
  • 0.75 ACPE Technician
  • 0.75 ABO
  • 0.75 ABP
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
  • 0.75 BDEA
$0.00
An interactive, online training session substance use disorders within emergency healthcare settings.
2025-2026 AUHCOP Resident Teaching and Learning Program
  • AUHCOP Resident Teaching and Learning Program (RTLP)
$100.00
Program Goals: 
Treatment of Clostridioides difficile Infection
  • Improving Antimicrobial Stewardship Across Alabama (IASAA)
  • 1.20 ABN
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
$0.00
This program will describe the risk factors associated with C. difficile infection (CID) and will focus on the current recommended treatment options, both pharmacotherapy and non-pharmacotherapy.  Additionally, the program will discuss new options that have recently come to the market for the treatment and prevention of CDI.
Recorded Treatment of Skin and Soft Tissue Infections (SSTIs), Diabetes-related Foot Infections (DFIs) and Osteomyelitis
  • Improving Antimicrobial Stewardship Across Alabama (IASAA)
  • 1.80 ABN
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
$0.00
Skin and soft tissues infections, diabetes-related foot infections, and osteomyelitis are frequently occurring infections among patients in both the inpatient and outpatient settings. Appropriate classification of these infections and recognition of the corresponding common causative pathogen are essential to determine optimal empiric antimicrobial therapy. This presentation will review types of SSTI and osteomyelitis along with common pathogens and discuss aspects of antimicrobial therapy for treatment of SSTI and osteomyelitis, including dosing, route, monitoring parameters and duration.
Recorded Treatment of Urinary Tract Infections
  • Improving Antimicrobial Stewardship Across Alabama (IASAA)
  • 1.80 ABN
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
$0.00
Urinary tract infections (UTIs) are one of the most common indications for receipt of antimicrobial therapy in both the community, hospital, and long-term care settings.  However, inappropriate use of broad-spectrum antibiotics for the treatment of UTIs has significantly contributed to the development of antimicrobial resistance to UTI pathogens.

Pages